|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 410-419.
Prepublished online as a Blood First Edition Paper on September 7, 2004; DOI 10.1182/blood-2004-05-1944.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
Franco Locatelli,
Peter Nöllke,
Marco Zecca,
Elisabeth Korthof,
Edoardo Lanino,
Christina Peters,
Andrea Pession,
Hartmut Kabisch,
Cornelio Uderzo,
Carmen S. Bonfim,
Peter Bader,
Dagmar Dilloo,
Jan Stary,
Alexandra Fischer,
Tom Révész,
Monika Führer,
Henrik Hasle,
Monika Trebo,
Marry M. van den Heuvel-Eibrink,
Susanna Fenu,
Brigitte Strahm,
Giovanna Giorgiani,
Mario Regazzi Bonora,
Ulrich Duffner, and
Charlotte M. Niemeyer, on behalf of the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group
From Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Germany; Department of Pediatric Immunology/Hematology and Stem Cell Transplantation, Leiden University Medical Center, The Netherlands; Divisione di Ematologia e Oncologia Pediatrica, Istituto G. Gaslini, Genova, Italy; St Anna Kinderspital, Wien, Austria; Clinica Pediatrica, Università di Bologna, Ospedale Sant'Orsola-Malpighi, Italy; Department of Oncology/Hematology, University Hospital Eppendorf, Hamburg, Germany; Clinica Pediatrica, Ospedale Nuovo San Gerardo, Monza, Italy; Hospital de Clinicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil; University Children's Hospital, University of Tübingen, Germany; Department of Pediatric Hematology and Oncology, Heinrich-Heine-University, Düsseldorf, Germany; Department of Pediatrics, University Hospital Motol, Prague, Czech Republic; Hematology-Oncology Unit, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands; von Haunersches, Kinderspital, Ludwig-Maximilians-Universität, München, Germany; Department of Pediatrics, Skejby Hospital, Aarhus University, Denmark; Dutch Childhood Leukemia Study Group, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands; Dipartimento di Ematologia, Università La Sapienza, Roma, Italy; and Dipartimento di Farmacologia Clinica, IRCCS Policlinico San Matteo, Pavia, Italy.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven curative therapy for juvenile myelomonocytic leukemia (JMML). We, the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group, report the outcome of 100 children (67 boys and 33 girls) with JMML given unmanipulated HSCT after a preparative regimen including busulfan, cyclophosphamide, and melphalan. Forty-eight and 52 children received transplants from an HLA-identical relative or an unrelated donor (UD), respectively. The source of hematopoietic stem cells was bone marrow, peripheral blood, and cord blood in 79, 14, and 7 children, respectively. Splenectomy had been performed before HSCT in 24 children. The 5-year cumulative incidence of transplantation-related mortality and leukemia recurrence was 13% and 35%, respectively. Age older than 4 years predicted an increased risk of disease recurrence. The 5-year probability of event-free survival for children given HSCT from either a relative or a UD was 55% and 49%, respectively (P = NS), with median observation time of patients alive being 40 months (range, 6 to 144). In multivariate analysis, age older than 4 years and female sex predicted poorer outcome. Results of this study compare favorably with previously published reports. Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling. (Blood. 2005;105:410-419)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Archambeault, N. J. Flores, A. Yoshimi, C. P. Kratz, M. Reising, A. Fischer, P. Noellke, F. Locatelli, P. Sedlacek, C. Flotho, et al.
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Blood,
February 1, 2008;
111(3):
1124 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Flotho, C. P. Kratz, E. Bergstrasser, H. Hasle, J. Stary, M. Trebo, M. M. van den Heuvel-Eibrink, D. Wojcik, M. Zecca, F. Locatelli, et al.
Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations
Blood,
January 15, 2008;
111(2):
966 - 967.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Koike and K. Matsuda
Evaluation of relationship between the genetic abnormalities and disease phenotype is required in juvenile myelomonocytic leukemia
Blood,
January 15, 2008;
111(2):
967 - 968.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hirano, M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, S. Kojima, and L. M. Nadler
Identification of an immunogenic CD8+ T-cell epitope derived from {gamma}-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia
Blood,
October 15, 2006;
108(8):
2662 - 2668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc.,
April 1, 2006;
81(4):
553 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Kratz, C. M. Niemeyer, R. P. Castleberry, M. Cetin, E. Bergstrasser, P. D. Emanuel, H. Hasle, G. Kardos, C. Klein, S. Kojima, et al.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
Blood,
September 15, 2005;
106(6):
2183 - 2185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
